AbbVie reports Phase 2 IMGN853-0420 data showing mirvetuximab soravtansine plus carboplatin delivered strong responses in FRα-positive platinum-sensitive ovarian cancer, with continued benefit during maintenance.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
AbbVie reported late-breaking results from the Phase 2 IMGN853-0420 trial evaluating mirvetuximab soravtansine-gynx in combination with carboplatin followed by continuation monotherapy in patients with folate receptor alpha (FRα)-expressing recurrent platinum-sensitive ovarian cancer. The data will be presented during an oral session at the 2026 Society of Gynecologic Oncology Annual Meeting.
The study enrolled 125 patients with FRα-positive measurable disease who had received one prior platinum-based regimen. Participants received mirvetuximab soravtansine-gynx plus carboplatin every three weeks for six to eight cycles, followed by single-agent mirvetuximab continuation. Nearly half of patients had prior exposure to PARP inhibitors, a population that may experience reduced responses to subsequent platinum therapy.
Strong Response Rates with Combination Induction
The primary endpoint assessed confirmed objective response rate (ORR) in the ≥50% FRα subgroup after six cycles. Confirmed ORR reached 62.7% in the ≥50% FRα subgroup and 62.4% in the overall population (FRα ≥25%). Approximately 81% of patients showed no disease progression and continued treatment with single-agent mirvetuximab, with a median duration of response of 11.2 months.
Continued Benefit During Maintenance Phase
Among patients transitioning to mirvetuximab monotherapy, ORR was 68% across the overall population. In patients with prior PARP inhibitor exposure, ORR was 63.9%, demonstrating activity in a population with limited treatment options.
Safety Profile Consistent with Prior Studies
The safety profile was consistent with earlier studies. The most common treatment-related adverse events were low-grade ocular events, including corneal changes that were reversible in more than 90% of patients. Grade ≥3 adverse events occurring in more than 5% of patients included neutropenia (15%), blurred vision (10%), thrombocytopenia (10%), cataract (6%), dry eye (5%), diarrhea (5%), and peripheral sensory neuropathy (5%).
Investigators Highlight ADC-Chemotherapy Strategy
Daejin Abidoye of AbbVie stated that platinum-sensitive ovarian cancer remains challenging as responses decline with recurrence and cumulative toxicities increase. He noted that the findings support mirvetuximab soravtansine as a potential novel regimen in this setting.
Primary investigator Gottfried E. Konecny added that the combination delivered strong responses, with many patients continuing to benefit during the monotherapy phase, supporting further evaluation of ADC-based approaches integrated with chemotherapy, including in patients previously treated with PARP inhibitors.
About the IMGN853-0420 Trial
IMGN853-0420 (NCT05456685) is a Phase 2 study evaluating carboplatin plus mirvetuximab soravtansine-gynx followed by continuation therapy in FRα-positive recurrent platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer after one prior platinum-based regimen. Participants without progressive disease after combination therapy continued on single-agent mirvetuximab soravtansine-gynx.
About ELAHERE®
ELAHERE® (minretumomabs soravtansine-gynx) is a first-in-class antibody-drug conjugate composed of a folate receptor alpha-binding antibody linked to the maytansinoid payload DM4, a tubulin inhibitor designed to selectively kill targeted cancer cells. Please see the full prescribing information for complete details on indication, boxed warning, and safety precautions.
Reference
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer, ClinicalTrials.gov ID NCT05456685, https://clinicaltrials.gov/study/NCT05456685
About the Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.